Skip to main content
Premium Trial:

Request an Annual Quote

uBiome Raises $83M in Series C Round

NEW YORK (GenomeWeb) – uBiome announced today that it has raised $83 million in a Series C financing round, led by OS Fund.

Other participants included 8VC, Y Combinator, Denstu Ventures, and additional new and existing investors.

uBiome said it will use the funding it raised for several projects, including expanding its product portfolio; leveraging its microbiome database to expand into drug R&D using pre-existing patent assets and industry research; speeding up commercialization of SmartGut, SmartJane, Explorer and other clinical tests under development; and starting commercialization of biopharmaceutical molecules and live biotherapeutics.

uBiome integrates precision sequencing technology with machine learning and artificial intelligence to develop wellness products, clinical tests, and therapeutic targets.  

"This financing allows us to expand our product portfolio, increase our focus on patent assets, and further raise our clinical profile, especially as we begin to focus on commercialization of drug discovery and development of our patent assets," uBiome Cofounder and CEO Jessica Richman said in a statement.

The Scan

Less Than Half

An effort to reproduce key findings from high-profile preclinical cancer studies finds less than half could be replicated, according to the Scientist.

Still Some SARS-CoV-2 Sequencing Holes

The Wall Street Journal reports that viral genomic surveillance has improved in the US, though says there are still gaps.

Avoiding Passing Them On

People with known disease-linked genetic variants are turning to in vitro fertilization so as to not pass those variants to their children, the Washington Post says.

PNAS Papers on Long Cell-Free DNA in Maternal Plasma, Genetic Propensity for Voting

In PNAS this week: long, cell-free DNA of maternal and fetal origins identified in maternal plasma, and more.